Life Sciences Regulation To Watch In 2013
"2013 could be a big year for regulation," said Areta L. Kupchyk, a Nixon Peabody partner who counsels clients on FDA interactions.
Here’s a look at key regulations experts will keep an eye on in 2013.
The Biosimilars Waiting Game
A lengthy wait for detailed guidance on biosimilars might finally end in...
To view the full article, register now.